Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | Enhancing personalized therapeutic cancer vaccine development

Chiara Bonini • 1 Apr 2022
ICLE 2022
General Vaccines

Chiara Bonini, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Institute, Milan, Italy, describes the current landscape of personalized therapeutic cancer vaccine development. She explains that early cancer vaccines had poor efficiency and did not elicit responses in large enough frequencies of patients, however, the combination of adoptive T cell therapy technology with tumor vaccination approaches allows lymphocytes to be sustained in patients for longer and offers the potential to have a clinical impact in a larger patient population. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

More from Chiara Bonini

1:57
Is WT1 a promising candidate peptide for TCR-based immunotherapies?
Chiara Bonini • 1 Apr 2022
1:38
Genome editing tools in T cell-based immunotherapies
Chiara Bonini • 1 Apr 2022
2:45
Cell therapy - progress to date and next steps
Chiara Bonini • 4 Apr 2016
2:44
The TK008 Phase III trial on using donor lymphoctyes to treat patients with high-risk acute leukemia
Chiara Bonini • 4 Apr 2016

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals